242 Wythe Ave #4, Brooklyn, NY 11249

First Investment Date

December 2023


Indaco Bio


Copenhagen, Denmark


Biotech and Pharma


Investment Status


Hoba Therapeutics, founded in 2016 by Novo Holdings and the Export and Investment Fund of Denmark (EIFO), is a Danish biotech company dedicated to developing novel therapeutic proteins for patients living with chronic neuropathic pain and hearing loss. The lead asset, HB-086, a non opioid compound, with a unique mode of action, targets the treatment of chronic neuropathic pain conditions. Neuropathic pain represents a significant unmet medical need, affecting more than 400 million patients worldwide.


Indaco has led, together with Medical Incubator Japan, a USD25M series A investment round, including Novo Holdings, EIR Ventures, EIFO and European Innovation Council Fund, that will enable Hoba Therapeutics to advance HB-086 through late pre-clinical development to the completion of Phase 1 clinical studies in patients for painful Chemotherapy-Induced Peripheral Neuropathy (CIPN).


Indaco Bio Fund has invested into Hoba Therapeutics in December 2023.